(Q37409321)

20 August 2017

Mutant KRAS is a druggable target for pancreatic cancer (English)

1 reference

20 August 2017

1 reference

25

Eithan Galun

0 references

author name string

Elina Zorde Khvalevsky

1

1 reference

20 August 2017

Racheli Gabai

2

1 reference

20 August 2017

Itzhak Haim Rachmut

3

1 reference

20 August 2017

Elad Horwitz

4

1 reference

20 August 2017

Zivia Brunschwig

5

1 reference

20 August 2017

Ariel Orbach

6

1 reference

20 August 2017

Adva Shemi

7

1 reference

20 August 2017

Talia Golan

8

1 reference

20 August 2017

Abraham J Domb

9

1 reference

20 August 2017

Eylon Yavin

10

1 reference

20 August 2017

Hilla Giladi

11

1 reference

20 August 2017

Ludmila Rivkin

12

1 reference

20 August 2017

Alina Simerzin

13

1 reference

20 August 2017

Rami Eliakim

14

1 reference

20 August 2017

Abed Khalaileh

15

1 reference

20 August 2017

Ayala Hubert

16

1 reference

20 August 2017

Maor Lahav

17

1 reference

20 August 2017

Yael Kopelman

18

1 reference

20 August 2017

Eran Goldin

19

1 reference

20 August 2017

Alan Dancour

20

1 reference

20 August 2017

Yael Hants

21

1 reference

20 August 2017

Sagit Arbel-Alon

22

1 reference

20 August 2017

Rinat Abramovitch

23

1 reference

20 August 2017

Amotz Shemi

24

1 reference

20 August 2017

language of work or name

English

0 references

publication date

2 December 2013

1 reference

Proceedings of the National Academy of Sciences of the United States of America

20 August 2017

6

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

20 August 2017

110

1 reference

20 August 2017

51

1 reference

20 August 2017

20723-20728

1 reference

Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870687

Biomaterial-based drug delivery systems for the controlled release of neurotrophic factors.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870687

Tumor budding cells, cancer stem cells and epithelial-mesenchymal transition-type cells in pancreatic cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870687

Biopolymer nanoparticle production for controlled release of biopharmaceuticals

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870687

Drug delivery systems with modified release for systemic and biophase bioavailability

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870687

Genetic and epigenetic alterations in pancreatic carcinogenesis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870687

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870687

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870687

Oncogene addiction: setting the stage for molecularly targeted cancer therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870687

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870687

Molecular genetics of pancreatic intraepithelial neoplasia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870687

In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870687

K-ras as a target for cancer therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870687

A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870687

Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870687

K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870687

Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870687

Diagnostic utility of K-ras mutations in fine-needle aspirates of pancreatic masses.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870687

Testing transgenic regulatory elements through live mouse imaging

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870687

Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870687

Molecular biology of pancreatic cancer

2 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24297898

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

In vitro cell migration and invasion assays

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24297898

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1073/PNAS.1314307110

1 reference

20 August 2017

0 references

1 reference

20 August 2017

PubMed publication ID

24297898

1 reference